On April 25, 2019, ZhongYin Law Firm entered into a legal service agreement with China National Pharmaceutical Investment Co., Ltd. (short name the CNPI). The team led by Wang Ting, Tan Jun and Wu Guanghong (senior partners of ZhongYin) has been engaged by the CNPI and will advise it on a specific investment project.

The CNPI, a wholly-owned subsidiary of China National Pharmaceutical Group Corporation, has a registered capital of RMB 1 billion and an asset under its management of over RMB 20 billion. With the strategic positioning of “based on the industry, serving the group, and being a professional investment and financing company in the medicine and big health industry”, the CNPI provides financing, equity investment, and other financial services in the fields closely related to the medicine and big health industry, and has established a development model of industry- finance integration with unique characteristics of the Sinopharm. It focuses on industrial merger and acquisition and industrial chain integration, and technology innovation and model innovation, and gives full play to its synergy influence in various industrial sectors within China National Pharmaceutical Group.

The team of Wang Ting, Tan Jun and Wu Guanghong currently consists of nearly twenty professional lawyers, has extensive experience and a large number of successful cases in practicing in domestic and overseas IPO and listing, refinancing of listed companies, M & A, reorganization, NEEQ listing, private equity and investment fund, foreign investment, bond issuance, asset securitization, regular legal counseling and other areas, and has a profound understanding of the PRC laws and regulations and regulatory practices, and thus can provide flexible, high-quality and value-adding legal services based on the different requirements of different clients.